The US Food and Drug Administration (FDA) has placed a partial hold on Molecular Templates’ Phase I trial of MT-0169 in patients with relapsed multiple myeloma.
The partial hold is based on the previously disclosed cardiac adverse events that occurred in two participants who received MT-0169 at 50mcg/kg dose.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,